Izalontamab

Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer[1].

Research Areas >> Cancer

Signaling Pathways >> JAK/STAT Signaling >> EGFR

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR

Izalontamab (5-46 mg/kg；静脉注射，每 7 天 1 次，共 4 次) 对不同类型肿瘤显示不同的抗肿瘤疗效[1]。 Animal Model: Female NOD/SCID mouse with SW48, FaDu and KYSE-150 xenografts[1] Dosage: 10, 25 and 46 mg/kg (SW48); 5, 10 and 25 mg/kg (FaDu and KYSE-150) Administration: Intravenous injection; 10, 25 and 46 mg/kg (SW48); 5, 10 and 25 mg/kg (FaDu and KYSE-150); every 7 days once, 4 doses in total Result: Dose-dependently inhibited the growth of FaDu and KYSE-150 tumors at the dose of 10 mg/kg. Inhibited 63.6% SW48 tumor growth at the dose of 46 mg/kg.

[1]. Xue J, et al. Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI-B001, an EGFR/HER3 Bi-specific Monoclonal Antibody. J Pharm Sci. 2020 Oct;109(10):3172-3180.